Research and Development 2021
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
LEO Pharma’s new R&D lead on driving agility in drug development
mike.hammerton@pharmaphorum.com
Deep Dive, Jörg Möller, LEO Pharma, patient-centric, R&D, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
Solving the “information challenge” of rare disease diagnosis
mike.hammerton@pharmaphorum.com
data, Deep Dive, neurological, R&D, rare disease, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
Digitalising drug discovery
mike.hammerton@pharmaphorum.com
Deep Dive, digital, Dr Maria Chatzou Dunford, Health data, Lifebit, R&D, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
Centessa’s founder on the new company’s unique R&D model
mike.hammerton@pharmaphorum.com
Centessa, Deep Dive, Francesco de Rubertis, Medicxi, R&D, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
The landscape for UK R&D SMEs post-COVID
mike.hammerton@pharmaphorum.com
Alderley Park, bruntwood SciTech, COVID-19, Deep Dive, R&D, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
Inside the UK’s leading efforts to restart clinical research
mike.hammerton@pharmaphorum.com
Clinical Research Network, covid, CRN, Deep Dive, National Institute for Health Research, NHS, NIHR, R&D, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
Focus on Rare: the invisible burden of rare diseases
mike.hammerton@pharmaphorum.com
Deep Dive, Emma Sutcliffe, Nexgen Healthcare Communications, patient insights, R&D, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
The post-COVID face of pharma research and development
mike.hammerton@pharmaphorum.com
Advanced Clinical, COVID-19, Deep Dive, pandemic, R&D, Research and Development 2021
0 Comment